Land: Storbritannia
Språk: engelsk
Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)
Zolmitriptan
Arrow Generics Ltd
N02CC03
Zolmitriptan
2.5mg
Orodispersible tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04070401; GTIN: 5060034835011
_PACKAGE LEAFLET: INFORMATION FOR THE USER_ _ZOLMITRIPTAN 2.5 MG ORODISPERSIBLE TABLETS_ _ZOLMITRIPTAN 5 MG ORODISPERSIBLE TABLETS_ Zolmitriptan READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. _1.WHAT ZOLMITRIPTAN ORODISPERSIBLE TABLETS _ _ARE AND WHAT THEY ARE USED FOR_ Zolmitriptan Orodispersible Tablets contain zolmitriptan and belong to a group of medicines called triptans. ZOLMITRIPTAN ORODISPERSIBLE TABLETS ARE USED TO TREAT MIGRAINE HEADACHE. • Migraine symptoms may be caused by the widening of blood vessels in the head. Zolmitriptan Orodispersible Tablets are thought to reduce the widening of these blood vessels. This helps to take away the headache and other symptoms of a migraine attack, such as feeling or being sick (nausea or vomiting) and being sensitive to light and sound. • Zolmitriptan Orodispersible Tablets work only when a migraine attack has started. They will not stop you from getting an attack. _2.BEFORE YOU TAKE ZOLMITRIPTAN ORODISPERSIBLE_ _TABLETS_ DO NOT TAKE ZOLMITRIPTAN ORODISPERSIBLE TABLETS IF: • you are allergic (hypersensitive) to zolmitriptan or any of the other ingredients of this medicine (see Section 6: Further information). • you have high blood pressure. • you have ever had heart problems, including a heart attack, angina (chest pain caused by exercise or effort), Prinzmetal's angina (chest pain which happens at rest) or have experienced heart related symptoms such as shortness of breath or pressure over the chest. • you have had a stroke or short-lasting symptoms similar to stroke (transient ischaemic attack or TIA). • you have severe Les hele dokumentet
OBJECT 1 ZOLMITRIPTAN 2.5 ORODISPERSIBLE TABLETS (ARROW) Summary of Product Characteristics Updated 14-Nov-2013 | Accord-UK Ltd 1. Name of the medicinal product Zolmitriptan 2.5 Orodispersible Tablets 2. Qualitative and quantitative composition Zolmitriptan Each 2.5 mg orodispersible tablet contains 2.5 mg of zolmitriptan. For a full list of excipients, see 6.1. 3. Pharmaceutical form Orodispersible tablet White, round, flat tablets with a diameter of 6.5 mm approximately. 4. Clinical particulars 4.1 Therapeutic indications Acute treatment of migraine headache with or without aura. 4.2 Posology and method of administration The recommended dose of Zolmitriptan Orodispersible Tablets to treat a migraine attack is 2.5 mg. It is advisable that Zolmitriptan Orodispersible Tablets is taken as early as possible after the onset of migraine headache but it is also effective if taken at a later stage. The tablet need not be taken with liquid; the tablet dissolves on the tongue and is swallowed with saliva. This formulation can be used in situations in which liquids are not available, or to avoid the nausea and vomiting that may accompany the ingestion of tablets with liquids. However, a delay in the absorption of zolmitriptan from Zolmitriptan Orodispersible Tablets can occur which may delay onset of action. The blister pack should be peeled open as shown on the foil (tablets should not be pushed through the foil). The Zolmitriptan tablet should be placed on the tongue, where it will dissolve and be swallowed with the saliva. If symptoms of migraine should recur within 24 hours, following an initial response, a second dose may be taken. If a second dose is required, it should not be taken within 2 hours of the initial dose. If a patient does not respond to the first dose, it is unlikely that a second dose will be of benefit in the same attack. If a patient does not achieve satisfactory relief with 2.5 mg doses, for subsequent attacks 5mg doses of Zolmitriptan Orodispersible Tablets could be considered. The total daily inta Les hele dokumentet